Allan Stephanie, Sinclair Fiona, Correia Marta, Fragkandrea-Nixon Ioanna, Phiri Alie, Jones Gareth, Thomson David, Yanga Francis, Brown George, McCann Mark, Simpson Sharon Anne, Evans Jonathan, Robb Katie, Gumley Andrew
University of Glasgow, Glasgow, UK
NHS Greater Glasgow and Clyde, Glasgow, UK.
BMJ Open. 2024 Dec 27;14(12):e090566. doi: 10.1136/bmjopen-2024-090566.
Fear of recurrence is a transdiagnostic problem experienced by people with psychosis, which is associated with anxiety, depression and risk of future relapse events. Despite this, there is a lack of available psychological interventions for fear of recurrence, and psychological therapies for schizophrenia are often poorly implemented in general. However, low-intensity psychological therapy is available for people who experience fear of recurrence in the context of cancer, which means there is an opportunity to learn what has worked in a well-implemented psychological therapy to see if any learning can be adapted for schizophrenia care. This article describes the design, methods and expected data collection of development, acceptab lity, feasibility, a d preliminary outcome signals for a copro uced low-intensity psycholo ical intervention targeting fear f relapse in people with schizophrenia (INDIGO), which aims to develop an acceptable psychological intervention for fear of recurrence.
INDIGO will use a mixed-methods approach to co-design and deliver a model and treatment pathway for a psychological intervention for people diagnosed with schizophrenia who experience fear of recurrence. The study will consist of four stages. First, in-depth interviews with mental health staff and people diagnosed with schizophrenia (with a further social network mapping task for patient participants only) to develop the intervention. Second, in-depth interviews with people who have accessed the Glasgow Fear of Recurrence service and oncology staff will be conducted to inform further development of the intervention. Third, co-design workshops will be held with people diagnosed with schizophrenia and mental health staff to co-design intervention content and the treatment pathway. Finally, people diagnosed with schizophrenia will be presented with an intervention prototype and invited to complete 'think-aloud' interviews to gather further feedback so adaptations can be implemented.
The INDIGO study received ethical approval from East Midlands-Nottingham 2 Research Ethics Committee (24/EM/0124). The study received independent peer review prior to funding. This co-design study is expected to lead to a future feasibility study and, if indicated, a randomised controlled trial.
对复发的恐惧是精神病患者面临的一个跨诊断问题，与焦虑、抑郁以及未来复发事件的风险相关。尽管如此，针对对复发的恐惧，目前缺乏可用的心理干预措施，而且精神分裂症的心理治疗总体上往往实施得很差。然而，针对癌症患者中出现对复发恐惧的人群，有低强度心理治疗可供使用，这意味着有机会了解在一种实施良好的心理治疗中有效的方法，看看能否将其中任何经验应用于精神分裂症护理。本文描述了一项针对精神分裂症患者中对复发恐惧的联合生产的低强度心理干预（INDIGO）的开发、可接受性、可行性及初步结果信号的设计、方法和预期数据收集情况，该干预旨在开发一种可接受的针对对复发恐惧的心理干预措施。
INDIGO将采用混合方法共同设计并提供一种针对被诊断患有精神分裂症且有对复发恐惧的人群的心理干预模型及治疗路径。该研究将包括四个阶段。首先，对心理健康工作人员和被诊断患有精神分裂症的人进行深入访谈（仅对患者参与者进行进一步的社会网络映射任务）以开发干预措施。其次，对使用过格拉斯哥复发恐惧服务的人和肿瘤学工作人员进行深入访谈，为干预措施的进一步开发提供信息。第三，与被诊断患有精神分裂症的人和心理健康工作人员举行联合设计研讨会，共同设计干预内容和治疗路径。最后，向被诊断患有精神分裂症的人展示干预原型，并邀请他们完成“出声思考”访谈以收集更多反馈，以便进行调整。
INDIGO研究获得了东米德兰兹 - 诺丁汉2研究伦理委员会（24/EM/0124）的伦理批准。该研究在获得资助前接受了独立同行评审。这项联合设计研究预计将促成未来的可行性研究，并在有指征时开展随机对照试验。
